http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022041491-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d3f980a22d785dfdded75479afcbcfa http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7bae7cf399c53b51787e575edaf8b820 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fd7956f86e0b46d69821365f1ba19f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d05dab97130cd65ce9453beaa4791a61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cba8de7f8a2eaddfd229605defb5e74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ecbd6d05779332f928bd0572ff9b390 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d16ff3aa08526457c1544e514b1c8995 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_624364545486aed4a8c6422b29512def http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce9f68d8351c0ae869f5057404a3fdbf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75ec31ac063af9906da21e87791e31fc |
| publicationDate | 2022-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022041491-A1 |
| titleOfInvention | Pyrrolo[2,3-d]pyrimidine derivative targeting egfr mutation, preparation method therefor and use thereof |
| abstract | The present invention relates to the field of chemical medicines, and provides a pyrrolo[2,3-d]pyrimidine derivative targeting EGFR mutation, a preparation method therefor and a use thereof. The derivative is a compound represented by formula I, or a salt thereof, or a stereoisomer thereof. The compound of the present invention has low toxicity to normal cells, has a significant inhibitory effect on lung cancer cell lines, particularly has good selectivity for EGFR mutant cells (HCC827 cells) and thus has a significant inhibitory effect; moreover, the compound of the present invention can effectively inhibit phosphorylation of EGFR. In addition, the compound of the present invention has good inhibitory activity and selectivity for mutant EGFR. The compound of the present invention can be used for treating lung cancer, particularly non-small cell lung cancer, has a strong inhibitory effect on EGFR mutant lung cancer, and has low toxicity; the compound of the present invention can also be used for preparing a tyrosine kinase inhibitor, particularly an EGFR phosphorylation inhibitor, and has good application prospects. |
| priorityDate | 2020-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 91.